Shandong Binzhou Zhiyuan Biotechnology Co.,Ltd. is located in boxing Economic Development Zone, a provincial key economic development zone in Shandong Province. It is a high-tech enterprise focusing on the R & D, production and application of cyclodextrin derivatives and cyclodextrin inclusion compounds. Founded in 2010, the company covers an area of 30000 ㎡, a construction area of 10000 ㎡, and fixed assets of 150 million yuan, of which the value of inspection instruments is more than 20 million yuan. It has a complete R & D, quality inspection center and professional scientific research team, maintains long-term cooperative relations with Nankai University, Shandong University and Fudan University, and has many R & D platforms at the provincial and municipal levels, It has successively undertaken a number of national and provincial major scientific research projects such as "science and technology helps the economy 2020" of the Ministry of science and technology. The company's products now have five categories and more than 50 varieties, involving medicine, daily chemical, functional foods, flavors and fragrances, new materials, medical dressing, natural pigments, contact lens care solutions, in vitro diagnostic reagents and other fields of application. The company has built a 2000 ㎡ high-standard GMP workshop and R & D, testing and pilot test laboratories. The testing instruments include more than 40 sets of semefi ion chromatograph, Beckmann capillary electrophoresis instrument, Shimadzu gas chromatograph and liquid chromatograph, infrared spectrometer and spectrophotometer, which can meet the independent testing of all items from the arrival of raw materials to the delivery of products. The company obtained the drug production license in 2013, and successively passed ISO9001 quality system certification, ISO14001:2015 environmental management system certification and ISO45001:2018 occupational health and safety management system certification. Hydroxypropyl beta cyclodextrin and sulfobutyl beta cyclodextrin sodium have been registered with FDA and successfully registered with CDE. Hydroxypropyl beta cyclodextrin oral grade Registration No. F20209990366 (transferred to "A"), injection grade Registration No. F20180001469, sulfobutyl beta cyclodextrin sodium CDE Registration No. F20190000285 have passed the on-site audit of association audit, and methyl beta cyclodextrin CDE Registration No. F2021000272 has been jointly declared with many well-known pharmaceutical enterprises at home and abroad. The products have independent intellectual property rights and are sold to Europe, the United States, Japan, South Korea, India, Pakistan, South America, the Middle East and other countries and regions. They have passed the audit of Pfizer, Johnson & Johnson, Gilead science, Xiansheng pharmaceutical, Lizhu Pharmaceutical Group and other domestic and foreign pharmaceutical enterprises, and have been greatly recognized and praised! At present, the company is a national high-tech enterprise, a national specialized and special "little giant" enterprise supported by the state in the 14th five year plan, a gazelle enterprise in Shandong Province, an "invisible champion" of small and medium-sized enterprises in Shandong Province, an enterprise with the "Silver Lion Award" for outstanding entrepreneurs in Binzhou City for three consecutive sessions, an enterprise on the white list of emerging industries in Binzhou City, and a contract abiding and trustworthy enterprise in Binzhou City. The company is the vice president unit of Binzhou Medical Care and Health Industry Association, the director unit of Binzhou chamber of Commerce of China International Chamber of Commerce and the director unit of Binzhou entrepreneur association.